EP3096620A1 - Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage - Google Patents

Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage

Info

Publication number
EP3096620A1
EP3096620A1 EP15702120.5A EP15702120A EP3096620A1 EP 3096620 A1 EP3096620 A1 EP 3096620A1 EP 15702120 A EP15702120 A EP 15702120A EP 3096620 A1 EP3096620 A1 EP 3096620A1
Authority
EP
European Patent Office
Prior art keywords
fibrous structure
bacteriophage
dry fibrous
dry
roll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15702120.5A
Other languages
German (de)
English (en)
Inventor
Paul Thomas Weisman
Duane Larry Charbonneau
Serena Rai HEYSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP3096620A1 publication Critical patent/EP3096620A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • D06M16/003—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

  • the present invention relates to fibrous structures comprising a surface care composition, and more particularly to dry fibrous structures comprising a surface care composition comprising one or more surface care agents, for example one or more bacteriophage, methods of making same, and methods for treating surfaces using same.
  • kitchen and bathroom surfaces such as floors, countertops, appliances, sinks, faucets, shower walls, tubs, toilets, and trash cans, are among the most heavily colonized by bacteria, and these spaces are likely where humans and our companion animals are the most exposed to the broadest diversity of bacteria.
  • Microbial exposure can arise both directly, for example from handling, preparing, and eating food, as well as indirectly, from contact with surfaces that harbor bacteria derived from a range of potential sources.
  • Kitchen and bathroom surfaces can harbor pathogenic bacteria such as Escherichia, Salmonella, Listeria, and Staphylococcus.
  • the kitchen has been implicated in having a number of surfaces highly susceptible to pathogenic bacterial contamination, including sink drains, sink basins, microwave interiors and exterior displays, garbage cans and disposals, faucet, refrigerator, oven, and microwave handles, oven doors, countertops, floors (particularly near sinks), produce and meat drawers (as well as other surfaces) within the refrigerators, stovetops, sponges, towels, and other dishcloths, and a variety of other kitchen surfaces (Flores et al., "Diversity, Distribution and Sources of Bacteria in Residential Kitchens," Environmental Microbiology, Volume 15, Issue 2, pp. 588 - 596 February 2013 (first published online November 2012, DOI: 10.1111/1462-2920.12036)).
  • Bathrooms are also problematic, having a tendency to harbor the foregoing pathogenic bacteria on surfaces such as toilets, including flush handles, faucet handles, sinks, bathtubs (including drains), showers, floors, and any other type of bathroom surface.
  • pathogenic bacteria such as Streptococcus, Escherichia, Salmonella, Listeria, Shigella, Campylobacter, Clostridium, and Staphylococcus, and particularly Streptococcus, Escherichia, Salmonella, and Staphylococcus.
  • Pathogenic bacteria can result in any of a variety of infections such as dermatitis, diaper rash, and impetigo, commonly caused by bacteria such as Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes, and Staphylococcus aureus, in which the elderly, infants, and pre-school children are particularly susceptible.
  • Other pathogenic conditions include other bacterial skin conditions such as urinary tract infections commonly suffered by women.
  • Diaper rash and other infections on skin are still common problems that are difficult to manage. Improved technologies are necessary to infect, lyse, destruct, disrupt, kill, inhibit the growth of, or otherwise reduce or eliminate these bacteria on surfaces.
  • fibrous structure that is more effective and/or efficient at reducing and/or eliminating bacteria from surfaces
  • a fibrous structure comprising a liquid composition comprising a bacteriophage.
  • a fibrous structure may require special packaging to maintain the effectiveness of the bacteriophage.
  • fibrous structure comprising a liquid composition will require special packaging to prevent the liquid composition from drying out during distribution of the product from the manufacturer to the consumer.
  • fibrous structure that is contacted at the time of use with a liquid composition comprising one or more bacteriophage.
  • a liquid composition comprising one or more bacteriophage.
  • such a system might require special packaging or bottling of the liquid composition comprising the bacteriophage to maintain the effectiveness of the bacteriophage until application of the liquid composition to a fibrous structure at the time of use.
  • One problem with the known fibrous structures is that they might require the use of a liquid composition comprising bacteriophage, which necessitates the use of special packaging to maintain the effectiveness of the bacteriophage until use or during distribution and storage of the liquid composition.
  • bacteriophage are prone to have decreased activity or potency upon exposure to sunlight or ultraviolet (UV) light. Such exposure has a damaging effect on the bacteriophage, decreasing lytic ability. Fibrous structures comprising bacteriophage might also be susceptible to such descreased bacteriophage activity upon exposure to sunlight or UV light. Accordingly, there is a need for a fibrous structure manufacturer to devise approaches or means for maintaining the activity of bacteriophage containing fibrous structures during distribution of the fibrous structure from the manufacturer, to the retailer, to the consumer, and finally while being stored before use in the consumer's dwelling.
  • UV ultraviolet
  • a firm roll conveys superior product quality and conveys sufficient fibrous structure material is present on the roll and consequently provides value for the consumer.
  • a firm roll is one with a lower % compressibility value. From the standpoint of a fibrous structure manufacturer, however, providing a firm roll or one with a low compressibility after a surface care agent, for example a bacteriophage, is incorporated into the fibrous structure is a challenge.
  • the fibrous structure manufacturer in order to provide a target roll diameter, while maintaining an acceptable cost of manufacture, the fibrous structure manufacturer must produce a finished fibrous structure roll having higher roll bulk.
  • One means of increasing roll bulk is to wind the fibrous structure roll loosely. Loosely wound rolls however, have low firmness or high compressibility and are easily deformed, which makes them unappealing to consumers.
  • the fibrous structure manufacturer's challenge becomes even greater as adding a surface care composition, especially an aqueous surface care composition, can decrease the bulk of the fibrous structure sheet and consequently decrease achievable roll bulk.
  • a rolled fibrous tissue product with high roll bulk and low % compressibility while comprising a high basis weight fibrous structure sheet spirally wound on the roll where the fibrous structure sheet provides greater absorbency, strength, and hand protection in use while simultaneously delivering surface care compositions to surfaces being treated or wiped.
  • a fibrous structure having high basis weight, greater absorbency, strength, spirally wound on a roll having high bulk and good roll firmness, while also comprising a surface care composition improvement of one of these properties typically comes at the expense of another.
  • the basis weight of the fibrous structure sheets is increased, achieving high roll bulk becomes more challenging since much of the bulk of the fibrous structure is achieved by molding of the embryonic fibrous structure web into the paper-making fabric and this bulk is decreased by increasing the basis weight of the fibrous structure sheet.
  • the bulk of the fibrous structure might be decreased by the addition of the surface care composition and then consequently have a negative impact on roll bulk, fibrous structure strength, and roll firmness.
  • a rolled fibrous structure product with a firm roll where a fibrous structure comprising a surface care composition is spirally wound on the roll.
  • a rolled fibrous structure product with a firm roll and also high roll bulk where a fibrous structure comprising a surface care composition is spirally wound on the roll.
  • the surface care composition comprises a one or more bacteriophage such that the negatives or tradeoffs associated with known fibrous structures are avoided, methods of making such fibrous structure rolls, and methods for using such fibrous structure rolls for treating surfaces in need of treatment, such as surfaces that are susceptible to bacterial contamination.
  • a dry fibrous structure comprising a bacteriophage composition comprising one or more bacteriophage such that the negatives associated with known fibrous structures are avoided, for example such that the dry fibrous structure does not need special packaging to maintain the effectiveness of the bacteriophage, methods of making such fibrous structures and methods for using such fibrous structures for treating surfaces in need of treatment, such as surfaces that are susceptible to bacterial contamination.
  • fibrous structure comprising surface care compositions, for example a surface care composition comprising bacteriophage, wherein the fibrous structure is capable of treating a one or more surfaces in need of treatment (for example a bacteria-contaminated surface) without negatively impacting the fibrous structure's physical properties such as strength, absorbency, roll bulk, % compressibility, modulus, elongation, and others.
  • fibrous structures comprising a surface care composition comprising one or more bacteriophage such that when such fibrous structures are used to treat surfaces, they provide efficacy against pathogenic bacteria in a variety of settings including in our homes, on skin and other epithelial tissue, and on any of a variety of other surfaces such as such as manufacturing plant surfaces and hospital surfaces.
  • the present invention fulfills the needs described above by providing dry fibrous structures comprising surface care compositions, for example surface care compositions comprising one or more bacteriophage, for example a bacteriophage composition, methods for making same, and methods for treating surfaces with same.
  • surface care compositions for example surface care compositions comprising one or more bacteriophage, for example a bacteriophage composition
  • methods for making same for example a bacteriophage composition
  • a dry fibrous structure comprising a surface care composition comprising one or more bacteriophage.
  • a dry fibrous structure avoids the need for special packaging in order to maintain the effectiveness of the bacteriophage.
  • the combination of the fibrous structure's for example dry fibrous structure's physical properties, such as superior absorbency, strength, softness, and hand protection in use, and its ability to treat surfaces, for example while simultaneously delivering bacteriophage to surfaces being treated or wiped without negatively impacting the fibrous structure's physical properties is realized as a result of depositing the surface care composition, for example bacteriophage composition and/or bacteriophage so that the composition and/or bacteriophage reside on a surface of the fibrous structure, for example dry fibrous structure.
  • the surface care composition for example bacteriophage composition and/or bacteriophage
  • a treated fibrous structure for example dry fibrous structure
  • the fibrous structure is in a dry state (for example a dry fibrous structure) to another surface being treated, for example wiped.
  • the dry transfer to a surface being treated with the fibrous structure, for example dry fibrous structure is sufficient to provide the treated surface with a bacteriophage level which influences bacteria growth on the treated surface.
  • fibrous structures for example dry fibrous structures, comprising one or more bacteriophage on its surface are unexpectedly realized through appropriate addition processes including printing and/or spraying of the surface care composition (bacteriophage composition) and/or bacteriophage onto a surface of the fibrous structure, for example dry fibrous structure.
  • these processes can be made to deliver the bacteriophage to the surface of the fibrous structure without altering its fiber spacing, bonding, and/or other micro structure properties, which means the bacteriophage treated fibrous structure of the present invention can exhibit superior absorbency, strength, softness, and hand protection in use that consumers desire.
  • the fibrous structure manufacturer allows the fibrous structure manufacturer to wind rolls with high roll bulk (for example greater than 4 cm /g) and firm roll compressibility (low % compressibility, for example less than 10% compressibility). While having the bacteriophage resident on the surface of the fibrous structure would make it susceptible to the UV light or sunlight deactivation, it was unexpectedly discovered that by spirally winding the fibrous structure, for example dry fibrous structure, comprising a surface care composition comprising one or more bacteriophage on a roll and/or also putting the fibrous structure and/or fibrous structure roll into a package where the package material prevents the transmittance of UV light or sun light simultaneously realizes the cancelation of this potential loss of bacteriophage viability.
  • high roll bulk for example greater than 4 cm /g
  • firm roll compressibility low % compressibility, for example less than 10% compressibility
  • a dry fibrous structure comprising a surface care composition comprising one or more bacteriophage.
  • a sanitary tissue product comprising a dry fibrous structure according to the present invention.
  • a method for making a dry fibrous structure according to the present invention comprising the step of contacting a fibrous structure with a surface care composition comprising one or more bacteriophage such that a dry fibrous structure comprising the surface care composition is produced, is provided.
  • a method for treating a surface in need of treatment comprises the step of contacting the surface with a dry fibrous structure according to the present invention.
  • a method for treating a surface in need of treatment comprises the steps of:
  • the present invention provides dry fibrous structures comprising a surface care composition comprising one or more bacteriophage, a method for making such dry fibrous structures, and a method for using such dry fibrous structures to treat surfaces in need of treatment.
  • Fig. 1 is a schematic representation of a Roll Diameter Tester used in the Percent
  • “Surface care composition” as used herein means a composition comprising one or more bacteriophage, for example one or more bacteriophage.
  • the surface care composition of the present invention may be referred to as a bacteriophage composition.
  • a "bacteriophage composition” as used herein means a composition comprising one or more bacteriophage.
  • the bacteriophage composition in addition to one or more bacteriophage, may further comprise positively charged compounds, such as tryptophan, lysine, or certain divalent cations (e.g., calcium, magnesium), or combinations thereof. Bacteria tend to be negatively charged, so adding positively charged elements to the bacteriophage composition may help associate the bacteriophages with nearby host bacteria.
  • the bacteriophage composition comprising one or more bacteriophage may further comprise a source of nutrition for the target bacteria, such as carbohydrate (e.g., monosaccharides), nucleotides (e.g., purines, pyrimadine), polymerase cofactor (e.g., manganese), or combinations thereof.
  • a source of nutrition for the target bacteria such as carbohydrate (e.g., monosaccharides), nucleotides (e.g., purines, pyrimadine), polymerase cofactor (e.g., manganese), or combinations thereof.
  • carbohydrate e.g., monosaccharides
  • nucleotides e.g., purines, pyrimadine
  • polymerase cofactor e.g., manganese
  • polymerase cofactor and nucleotides may be particularly helpful, as these are nutrients which are specifically required for the host bacterium to manufacture new bacteriophages.
  • Bacteriophage as used herein means a virus that infects and replicates within bacteria. The term is derived from “bacteria” and the Greek word phagein, which means "to devour”. Bacteriophages are composed of proteins that encapsulate a DNA and/or RNA genome, and may have relatively simple and/or elaborate structures. Their genomes may encode a few or over hundreds of genes. The bacteriophages replicate within bacteria following their injection of their genome into the bacteria's cytoplasm. Bacteriophages may be lytic or otherwise harmful to the bacteria of one or more undesirable bacteria strains.
  • Undesirable bacteria strains may be or may produce compounds which are potentially pathogenic for humans and/or animals, and/or may be associated with spoilage, malodor, aesthetic decline, or other deterioration of a food product colonized by the undesirable bacteria.
  • bacterium or “target bacterium” refers to an undesirable micro-organism susceptible to infection and lysis, apoptosis, or alternate modes of cell death caused by a bacteriophage. Different bacteriophage may infect different strains of bacteria with different results and/or may infect some strains of bacteria but not others.
  • bacteriophages are naturally-occurring biological agents, viral in nature, that infect and replicate within bacteria. They are the most abundant and diverse biological entities on earth, naturally existing in seawater, fresh water, soil and generally wherever bacteria are present. Many types of bacteriophages kill their host bacteria cell after infection and replication. Because bacteriophages are absolutely specific to a particular type of host bacteria, however, they do not affect humans or animals.
  • Suitable bacteriophage may be selected based on the food and the pathogenic bacteria of interest. For example, for pet food kibble, Salmonella is a particular concern. Salmonella is common in chicken and chicken meal, which are common ingredients in dry or semi-moist pet food kibble. Salmonella is typically killed during food production, but because materials often handled in the plant may contain Salmonella, there is a chronic risk of contaminating finished product. Even tiny numbers of Salmonella bacteria can be problematic, as nutrient-rich food, such as pet food kibble, may be hospitable to bacterial growth. Exemplary bacteriophage that are lytic for certain species or strains of Salmonella (or other bacteria) include those described in U.S. Patent No. 7,674,467; U.S. Patent No.
  • the suitable bacteriophage of the present invention are and/or include bacteriophage of the Siphoviridae, Podoviridae, or Myoviridae families, or combinations thereof.
  • the bacteriophage may be wild-type or genetically modified or combinations thereof.
  • the bacteriophage may be infective and lytic or otherwise fatal with respect to at least one species or strain of bacteria of the genus Streptococcus, Enterobacterium, Escherichia, Salmonella, Listeria, Shigella, Campylobacter or combinations thereof.
  • Fibrous structure as used herein means a structure that comprises one or more fibrous filaments and/or fibers.
  • a fibrous structure according to the present invention means an orderly arrangement of filaments and/or fibers within a structure in order to perform a function.
  • Non-limiting examples of fibrous structures of the present invention include paper, fabrics (including woven, knitted, and non- woven), and absorbent pads (for example for diapers or feminine hygiene products).
  • Non-limiting examples of processes for making fibrous structures include known wet-laid processes, such as wet-laid papermaking processes, and air-laid processes, such as air-laid papermaking processes.
  • Wet-laid and/or air-laid papermaking processes typically include a step of preparing a composition comprising a plurality of fibers that are suspended in a medium, either wet, more specifically aqueous medium, or dry, more specifically gaseous medium, such as air.
  • the aqueous medium used for wet-laid processes is oftentimes referred to as a fiber slurry.
  • the fiber composition is then used to deposit a plurality of fibers onto a forming wire or belt such that an embryonic fibrous structure is formed, after which drying and/or bonding the fibers together results in a fibrous structure. Further processing the fibrous structure may be carried out such that a finished fibrous structure is formed.
  • the finished fibrous structure is the fibrous structure that is wound on the reel at the end of papermaking, and may subsequently be converted into a finished product, e.g. a sanitary tissue product.
  • Non-limiting examples of other known processes and/or unit operations for making fibrous structures include fabric crepe and/or belt crepe processes, ATMOS processes, NTT processes, through-air-dried processes, uncreped through-air-dried processes, and conventional wet press processes.
  • Another process that can be used to produce the fibrous structures is a melt-blowing, dry spinning, and/or spunbonding process where a polymer composition is spun into filaments and collected on a belt to produce a fibrous structure.
  • a plurality of fibers may be mixed with the filaments prior to collecting on the belt and/or a plurality of fibers may be deposited on a prior produced fibrous structure comprising filaments.
  • the fibrous structures of the present invention may be homogeneous or may be layered in the direction normal to the machine direction. If layered, the fibrous structures may comprise at least two and/or at least three and/or at least four and/or at least five layers.
  • the fibrous structures of the present invention may be co-formed fibrous structures.
  • "Co-formed" as used herein means that the fibrous structure comprises a mixture of at least two different components wherein at least one of the components comprises a filament, such as a polypropylene filament, and at least one other component, different from the first component, comprises a solid additive, such as a fiber and/or a particulate.
  • a co-formed fibrous structure comprises solid additives, such as fibers, such as wood pulp fibers and/or absorbent gel articles of manufacture and/or filler particles and/or particulate spot bonding powders and/or clays, and filaments, such as polypropylene filaments.
  • a co-formed structure comprises those described in U.S. Patent No. 8,017,534.
  • the fibrous structures of the present invention may comprise man-made fibers, natural fibers, and combinations thereof, and may or may not be biodegradable.
  • man-made fibers include: rayon, which in turn includes but is not limited to viscose, lyocell and mixtures thereof; polyhydroxyalkanoates; polylactic acid; polyester; and mixtures thereof.
  • natural fibers include: pulp, cotton, wool, silk, jute, linen, ramie, hemp, flax, camel hair, kenaf, bamboo, and mixtures thereof.
  • Non-thermoplastic fibers that are of use in the present invention are selected from the group consisting of: rayon, which in turn includes but is not limited to viscose, lyocell and mixtures thereof; pulp; cotton; wool; silk; jute; linen; ramie; hemp; flax; camel hair; kenaf; and mixtures thereof.
  • the fibrous structures of the present invention may be manufactured via fiber laying, fiber bonding, or combinations thereof.
  • Fiber laying steps known in the art include, but are not limited to, spunlaying, meltblowing, carding, airlaying, wetlaying and combinations thereof, of the filaments and/or fibers comprising the fibrous structure.
  • Fiber bonding steps known in the art include, but are not limited to, spunlacing (or hydroentangling), cold calendering, hot calendering, air thru bonding, chemical bonding, needle punching and combinations thereof.
  • the dry fibrous structure comprises a fibrous structure selected from the group consisting of: air-laid fibrous structures, wet-laid fibrous structures, high loft nonwoven fibrous structures, needlepunched fibrous structures, hydroentangled fibrous structures, fiber tow fibrous structures, woven fibrous structures, knitted fibrous structures, flocked fibrous structures, spunbond fibrous structures, carded fibrous structures, spunbond/meltblown fibrous structures, spunbond/meltblown/spunbond fibrous structures, meltblown fibrous structures, carded fibrous structures, coform fibrous structures, and combinations thereof.
  • a fibrous structure selected from the group consisting of: air-laid fibrous structures, wet-laid fibrous structures, high loft nonwoven fibrous structures, needlepunched fibrous structures, hydroentangled fibrous structures, fiber tow fibrous structures, woven fibrous structures, knitted fibrous structures, flocked fibrous structures, spunbond fibrous structures, carded fibrous structures, spunbond/meltblown fibrous structures, spunbond/meltblown/
  • “Dry fibrous structure” as used herein means that the fibrous structure exhibits a moisture (water) content of less than 20% and/or less than 15% and/or less than 10% and/or less than 7% and/or less than 5% and/or less than 3% and/or less than 1% to 0% and or to greater than 0% by weight of the dry fibrous structure as measured according to the Water Content Test Method described herein.
  • the dry fibrous structure of the present invention exhibits a moisture (water) content of from about 0.0001% to about 20% and/or from about 0.001% to about 15% and/or from about 0.001% to about 12% and/or from about 0.001% to about 10% and/or from about 0.001% to about 7% and/or from about 0.001% to about 5%, by weight of the dry fibrous structure.
  • Fiber and/or “Filament” as used herein means an elongate particulate having an apparent length greatly exceeding its apparent width, i.e. a length to diameter ratio of at least about 10.
  • a "fiber” is an elongate particulate as described above that exhibits a length of less than 5.08 cm (2 in.) and a “filament” is an elongate particulate as described above that exhibits a length of greater than or equal to 5.08 cm (2 in.).
  • Fibers are typically considered discontinuous in nature.
  • fibers include wood pulp fibers and synthetic staple fibers such as polyester fibers.
  • Filaments are typically considered continuous or substantially continuous in nature. Filaments are relatively longer than fibers.
  • Non-limiting examples of filaments include meltblown and/or spunbond filaments.
  • Non-limiting examples of materials that can be spun into filaments include natural polymers, such as starch, starch derivatives, cellulose and cellulose derivatives, hemicellulose, hemicellulose derivatives, chitin, chitosan, polyisoprene (cis and trans), peptides, polyhydroxyalkanoates, and synthetic polymers including, but not limited to, thermoplastic polymer filaments comprising thermoplastic polymers, such as polyesters, nylons, polyolefins such as polypropylene filaments, polyethylene filaments, polyvinyl alcohol and polyvinyl alcohol derivatives, sodium polyacrylate (absorbent gel material) filaments, and copolymers of polyolefins such as polyethylene-octene, and biodegradable or compostable thermoplastic fibers such as polylactic acid filaments, polyviny
  • the filament comprises a thermoplastic polymer selected from the group consisting of: polypropylene, polyethylene, polyester, polylactic acid, polyhydroxyalkanoate, polyvinyl alcohol, polycaprolactone, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer, poly-urethane, and mixtures thereof.
  • the filament comprises a thermoplastic polymer is selected from the group consisting of: polypropylene, polyethylene, polyester, polylactic acid, polyhydroxyalkanoate, polyvinyl alcohol, polycaprolactone, and mixtures thereof.
  • the filaments may be monocomponent or multicomponent, such as bicomponent filaments.
  • the filaments exhibits an average fiber diameter of less than 50 ⁇ and/or less than 25 ⁇ and/or less than 15 ⁇ and/or less than 12 ⁇ (also referred to as "microfilaments") and/or less than 10 ⁇ and/or less than 6 ⁇ .
  • fiber refers to papermaking fibers.
  • Papermaking fibers useful in the present invention include cellulosic fibers commonly known as wood pulp fibers.
  • Applicable wood pulps include chemical pulps, such as Kraft, sulfite, and sulfate pulps, as well as mechanical pulps including, for example, groundwood, thermomechanical pulp and chemically modified thermomechanical pulp. Chemical pulps, however, may be preferred since they impart a superior tactile sense of softness to tissue sheets made therefrom. Pulps derived from both deciduous trees (hereinafter, also referred to as "hardwood”) and coniferous trees (hereinafter, also referred to as "softwood”) may be utilized. The hardwood and softwood fibers can be blended, or alternatively, can be deposited in layers to provide a stratified web.
  • hardwood deciduous trees
  • softwood coniferous trees
  • 3,994,771 are incorporated herein by reference for the purpose of disclosing layering of hardwood and softwood fibers.
  • fibers derived from recycled paper which may contain any or all of the above categories as well as other non-fibrous materials such as fillers and adhesives used to facilitate the original papermaking.
  • wood pulp fibers In addition to the various wood pulp fibers, other fibers such as cotton linters, rayon, lyocell, trichomes, seed hairs, and bagasse can be used in this invention.
  • other fibers such as cotton linters, rayon, lyocell, trichomes, seed hairs, and bagasse can be used in this invention.
  • sources of cellulose in the form of fibers or capable of being spun into fibers include grasses and grain sources.
  • sanitary tissue product as used herein means a soft, low density (i.e. ⁇ about 0.15 g/cm ) web useful as a wiping implement for post-urinary and post-bowel movement cleaning (toilet tissue), for otorhinolaryngological discharges (facial tissue), and multi-functional absorbent and cleaning uses (absorbent towels).
  • suitable sanitary tissue products of the present invention include paper towels, bath tissue, facial tissue, napkins, baby wipes, adult wipes, wet wipes, cleaning wipes, polishing wipes, cosmetic wipes, car care wipes, wipes that comprise an active agent for performing a particular function, cleaning substrates for use with implements, such as a Swiffer ® cleaning wipe/pad.
  • the sanitary tissue product may be convolutedly wound upon itself about a core or without a core to form a sanitary tissue product roll.
  • the sanitary tissue product of the present invention comprises a fibrous structure, for example a dry fibrous structure, according to the present invention.
  • the sanitary tissue products and/or fibrous structures of the present invention may exhibit a basis weight between about 5 g/m 2 to about 120 g/m 2 and/or from about 10 g/m 2 to about 120 g/m 2 and/or from about 15 g/m 2 to about 110 g/m 2 and/or from about 20 g/m 2 to about 100 g/m 2 and/or from about 30 to 90 g/m as measured according to the Basis Weight Test Method described herein.
  • the sanitary tissue product of the present invention may exhibit a basis weight between about 40 g/m 2 to about 120 g/m 2 and/or from about 50 g/m 2 to about 110 g/m 2 and/or from about 55 g/m 2 to about 105 g/m 2 and/or from about 60 to 100 g/m 2 as measured according to the Basis Weight Test Method described herein.
  • the sanitary tissue products and/or fibrous structures of the present invention may exhibit an initial total wet tensile strength of less than about 78 g/cm (200 g/in) and/or less than about 59 g/cm (150 g/in) and/or less than about 39 g/cm (100 g/in) and/or less than about 29 g/cm (75 g/in).
  • the sanitary tissue products and/or fibrous structures of the present invention may exhibit an initial total wet tensile strength of at least 118 g/cm (300 g/in) and/or at least 157 g/cm (400 g/in) and/or at least 196 g/cm (500 g/in) and/or at least 236 g/cm (600 g/in) and/or at least 276 g/cm (700 g/in) and/or at least 315 g/cm (800 g/in) and/or at least 354 g/cm (900 g/in) and/or at least 394 g/cm (1000 g/in) and/or from about 118 g/cm (300 g/in) to about 1968 g/cm (5000 g/in) and/or from about 157 g/cm (400 g/in) to about 1181 g/cm (3000 g/in) and or from about 196 g
  • the sanitary tissue products and/or fibrous structures of the present invention may exhibit a density of less than about 0.60 g/cm 3 and/or less than about 0.30 g/cm 3 and/or less than about 0.20 g/cm 3 and/or less than about 0.10 g/cm 3 and/or less than about 0.07 g/cm 3 and/or less than about 0.05 g/cm 3 and/or from about 0.01 g/cm 3 to about 0.20 g/cm 3 and/or from about 0.02 g/cm 3 to about 0.10 g/cm as measured according to the Density Test Method described herein.
  • the sanitary tissue products of the present invention may be in the form of sanitary tissue product rolls.
  • Such sanitary tissue product rolls may comprise a plurality of connected, but perforated sheets of fibrous structure, that are separably dispensable from adjacent sheets.
  • one or more ends of the roll of sanitary tissue product may comprise an adhesive and/or dry strength agent to mitigate the loss of fibers, especially wood pulp fibers from the ends of the roll of sanitary tissue product.
  • the sanitary tissue products and/or fibrous structures of the present invention may comprises additives such as softening agents, temporary wet strength agents, permanent wet strength agents, bulk softening agents, lotions, silicones, wetting agents, latexes, especially surface-pattern-applied latexes, dry strength agents such as carboxymethylcellulose and starch, absorbency aids, and other types of additives suitable for inclusion in and/or on sanitary tissue products.
  • additives such as softening agents, temporary wet strength agents, permanent wet strength agents, bulk softening agents, lotions, silicones, wetting agents, latexes, especially surface-pattern-applied latexes, dry strength agents such as carboxymethylcellulose and starch, absorbency aids, and other types of additives suitable for inclusion in and/or on sanitary tissue products.
  • Basis Weight as used herein is the weight per unit area of a sample reported in lbs/3000 ft or g/m and is measured according to the Basis Weight Test Method described herein.
  • Roll Bulk as used herein is the volume of paper divided by its mass on the wound roll. Roll Bulk is calculated by multiplying ⁇ (3.142) by the quantity obtained by calculating the difference of the roll diameter squared in cm squared (cm ) and the outer core diameter squared in cm squared (cm ) divided by 4, divided by the quantity sheet length in cm multiplied by the sheet count multiplied by the Bone Dry Basis Weight of the sheet in grams (g) per cm squared (cm ) as measured according to the Basis Weight Test Method described herein.
  • Machine Direction or “MD” as used herein means the direction parallel to the flow of The fibrous structure through the fibrous structure making machine and/or sanitary tissue product manufacturing equipment.
  • Cross Machine Direction or “CD” as used herein means the direction parallel to the width of the fibrous structure making machine and/or sanitary tissue product manufacturing equipment and perpendicular to the machine direction.
  • Ply as used herein means an individual, integral fibrous structure.
  • Plies as used herein means two or more individual, integral fibrous structures disposed in a substantially contiguous, face-to-face relationship with one another, forming a multi-ply fibrous structure and/or multi-ply sanitary tissue product. It is also contemplated that an individual, integral fibrous structure can effectively form a multi-ply fibrous structure, for example, by being folded on itself. Fibrous Structure
  • the fibrous structures of the present invention comprise a surface care composition comprising one or more bacteriophage.
  • the surface care composition (bacteriophage composition) of the present invention may be releasably associated with the fibrous structures, for example may be present primarly on or substantially on one or more surfaces of the fibrous structures, such that at least a portion of the surface care composition (bacteriophage composition); namely, one or more bacteriophages within the one or more bacteriophage is transferred to a surface upon contact, with or without pressure and/or wiping, by the fibrous structures.
  • the surface care composition of the present invention comprising one or more bacteriophages is transferable from the fibrous structure, for example dry fibrous structure, to a surface during use by a consumer.
  • at least a portion of the surface care composition is present on a surface of the fibrous structure, for example dry fibrous structure.
  • the fibrous structures of the present invention may be particularly advantageous because the transfer of a bacteriophage to a surface to be treated, such as a bathroom or kitchen surface (e.g., a countertop), presents a challenge in view of the non-motile nature of bacteriophages generally.
  • bacteriophages are incorporated into and/or applied to a solid material, wherein efficacy may depends in part on transfer of the bacteriophages from a solid material, such as a dry fibrous structure of the present invention. Because the bacteriophages do not move after application to a solid material, such as a dry fibrous structure (aside from possible Brownian motion), they may only be effective in disrupting or otherwise harming bacterial contamination if live bacteria happens to come into contact with the fixed-position bacteriophage for a sufficient period of time.
  • the present inventive dry fibrous structures comprising a bacteriophage composition facilitate the transfer of the bacteriophage and/or bacteriophages onto a surface susceptible to bacterial contamination, such as hard surfaces found in the home, manufacturing plants, hospitals, or the like, to reduce and/or eliminate the bacteria present on the surface.
  • the dry fibrous structure is used to treat a surface (in need of treatment) that is susceptible to colonization by undesirable bacteria, such as any or a combination of bacteria described herein.
  • the surface may be human and/or animal skin, such as infant skin or wounded skin.
  • the surface to be treated may be a hard surface, such as a bathroom, kitchen, floor, or other household surface, or it may be an industrial surface, such as any surface within a manufacturing plant.
  • the surface to be treated by the dry fibrous structure of the present invention may be dry or substantially dry, such as a kitchen or bathroom countertop, or other hard surface when contacted with the dry fibrous structure.
  • the surface to be treated by the dry fibrous structure may be wet (have a liquid present thereon), such as a kitchen or bathroom countertop, or other hard surface, that has been, for example, sprayed with a traditional cleaning solution or even merely water or another liquid when contacted with the dry fibrous structure.
  • the dry fibrous structure may be contacted with a liquid, such as water or other cleaning solution to produce a liquid-containing fibrous structure, prior to the contacting the surface to be treated, which may itself be dry or substantially dry or wet.
  • a liquid such as water or other cleaning solution
  • a method for treating a surface in need of treatment using a dry fibrous structure comprises the step of contacting the surface with a liquid concurrently with contacting the surface with the dry fibrous structure.
  • a method for treating a surface in need of treatment using a dry fibrous structure comprises the steps of contacting the dry fibrous structure with a liquid to produce a liquid-containing fibrous structure and then contacting a surface with or without a liquid concurrently with or prior to contacting the surface with the liquid containing fibrous structure.
  • the dry fibrous structure may comprise one or more indicia that communicate the presence or absence or level of any surface care composition (bacteriophage composition) and/or bacteriophages present on the dry fibrous structure.
  • the indicia may be selected from the group consisting of: (1) communication to a user that a surface care composition (bacteriophage composition) and/or bacteriophage is present or absent on the fibrous structure; (2) indicia for communication to a user that at least a portion of the surface care composition (bacteriophage composition) and/or bacteriophage has been transferred from the dry fibrous structure to a surface; and (3) any combination thereof.
  • the dry fibrous structure comprises indicia for communication to a user that a surface care composition (bacteriophage composition) and/or bacteriophage is present on and/or in the dry fibrous structure.
  • a surface care composition bacteriophage composition
  • bacteriophage composition resides on one side of the planar paper towel, but not the other.
  • such side could contain an indicator such as a sensor, colors, ink, dye, pigment, shading, design, picture, word, symbol, graphic, image, or any combination thereof, or any of a variety of other indicators that communicates to the user that such side of the planar paper towel should be the side that is contacted to the surface while in use.
  • an indicator such as a sensor, colors, ink, dye, pigment, shading, design, picture, word, symbol, graphic, image, or any combination thereof, or any of a variety of other indicators that communicates to the user that such side of the planar paper towel should be the side that is contacted to the surface while in use.
  • the paper towel could contain a colored indicator that communicates that a certain amount of bacteriophage composition and/or bacteriophage resides on and/or in the paper towel, and this colored indicator could change in some manner once at least a portion of the bacteriophage composition and/or bacteriophage is transferred from the paper towel (dry fibrous structure) to the desired surface (e.g., a kitchen countertop).
  • This and the foregoing indicators may be present on the dry fibrous structure via any of a variety of different mechanisms such as, for example, printing the bacteriophage composition and/or bacteriophage and the indicia onto a surface of the fibrous structure to produce the dry fibrous structure of the present invention.
  • the bacteriophage composition further comprises the indicia.
  • the dry fibrous structures of the present invention comprise at least 10 and/or at least 10 and/or at least 10 3 and/or at least 10 4 and/or at least 10 5 and/or at least 10 6 PFUs (plaque-forming units) of the one or more bacteriophage.
  • the dry fibrous structures of the present invention comprise from about 10 to about 10 10 and/or from about 10 to about 10 9 and/or from about 10 2 to about 10 9 and/or from about 10 3 to about 10 9 and/or from about 10 3 to about 10 8 PFUs of the one or more bacteriophage.
  • the dry fibrous structures of the present invention comprise from about 10 to about 10 10 and/or from about 10 to about 10 9 and/or from about 10 2 to about 10 9 and/or from about 10 3 to about 10 9 and/or from about 10 3 to about 10 8 PFUs of the one or more bacteriophage.
  • the dry fibrous structures of the present invention comprise from about 10 to about 10 10 and/or from about 10 to about 10 9 and/or from about
  • inventions comprise from about 10 to about 10 and/or from about 10 to about 10 and/or from about 10 3 to about 10 6 PFUs/cm 2 of the one or more bacteriophage.
  • the dry fibrous structures of the present invention exhibit a geometric mean (GM) Peak Elongation of greater than 10% and/or greater than 15% and/or greater than 20% and/or greater than 25% as measured according to the Tensile Test Method described herein.
  • GM geometric mean
  • the dry fibrous structures of the present invention exhibit a geometric mean (GM) Dry Tensile Strength of greater than 200 g/in and/or greater than 250 g/in and/or greater than 300 g/in and/or greater than 350 g/in and/or greater than 400 g/in and/or greater than 500 g/in and/or greater than 750 g/in as measured according to the Tensile Test Method described herein.
  • GM geometric mean
  • the dry fibrous structures of the present invention exhibit a geometric mean (GM) Modulus of less than 20,000 and/or less than 15,000 and/or less than 10,000 and/or less than 5,000 and/or less than 3,000 and/or less than 1,500 and/or less than 1,200 to about 0 and/or to about 100 and/or to about 300 and/or to about 500 and/or to about 700 g/cm at 15 g/cm as measured according to the Tensile Test Method described herein.
  • GM geometric mean
  • the dry fibrous structures of the present invention may further comprise a skin care lotion or a carrier lotion.
  • the skin care lotion may be a component of the bacteriophage composition, or it may be a separate composition.
  • suitable lotions include, but are not limited to, those described in U.S. Pat. Nos. 5,607,760; 5,609,587; 5,635,191; 5,643,588; and 5,968,025, and as described in U.S. Application No. 61/391,353.
  • Bacteriophage compositions may be applied onto the skin care composition, for example, in the manner described in U.S. Pat. No.
  • sections of the dry fibrous structure may comprise the skin care lotion, while adjacent areas of the dry fibrous structure may comprise a bacteriophage composition.
  • the bacteriophage composition and the skin care lotion may be stripes oriented in a longitudinal direction of the dry fibrous structure.
  • any of the fibrous structures of the present invention described herein comprising a surface care composition comprising one or more bacteriophage may be in the form of a roll of fibrous structure (single-ply or multi-ply), for example a dry fibrous structure roll, and may exhibit a roll bulk (in units of cm /g) of greater than 4 and/or greater than 6 and/or greater than 8 and/or greater than 10 and/or greater than 12 and/or to about 20 and/or to about 18 and/or to about 16 and/or to about 14 and/or from about 4 to about 20 and/or from about 4 to about 12 and/or from about 8 to about 20 and/or from about 12 to about 16.
  • any of the fibrous structures of the present invention described herein comprising a surface care composition comprising one or more bacteriophage may be in the form of a roll of fibrous structure (single-ply or multi-ply), for example a dry fibrous structure roll, and may exhibit a % compressibility (in units of %) of less than 10 and/or less than 8 and/or less than 7 and/or less than 6 and/or less than 5 and/or less than 4 and/or less than 3 to about 0 and/or to about 0.5 and/or to about 1 and/or from about 4 to about 10 and/or from about 4 to about 8 and/or from about 4 to about 7 and/or from about 4 to about 6 as measured according to the Percent Compressibility Test Method described herein.
  • any of the fibrous structures of the present invention described herein comprising a surface care composition comprising one or more bacteriophage may be in the form of a roll of fibrous structure (single-ply or multi-ply), for example a dry fibrous structure roll, and may exhibit a roll bulk (in units of cm /g) of greater than 4 and/or greater than 6 and/or greater than 8 and/or greater than 10 and/or greater than 12 and/or to about 20 and/or to about 18 and/or to about 16 and/or to about 14 and/or from about 4 to about 20 and/or from about 4 to about 12 and/or from about 8 to about 20 and/or from about 12 to about 16 and a % compressibility (in units of %) of less than 10 and/or less than 8 and/or less than 7 and/or less than 6 and/or less than 5 and/or less than 4 and/or less than 3 to about 0 and/or to about 0.5 and/or to about 1 and/or from about 4 to about 10 and/
  • such a dry fibrous structure roll exhibits a roll bulk of greater than 4 cm /g and a % compressibility of less than 10% as measured according to the Percent Compressibility Test Method. In another example, such a dry fibrous structure roll exhibits a roll bulk of greater than 6 cm /g and a % compressibility of less than 8% as measured according to the Percent Compressibility Test Method. In still another example, such a dry fibrous structure roll exhibits a roll bulk of greater than 8 cm /g and a % compressibility of less than 7% as measured according to the Percent Compressibility Test Method.
  • One or more of the fibrous structures of the present invention described herein comprising a surface care composition comprising one or more bacteriophage may be in the form of a roll of fibrous structure (single-ply or multi-ply), for example a dry fibrous structure roll, and may be packaged in a package, such as a film package, comprising a one or more, for example a plurality of dry fibrous structure rolls.
  • package material for example films, may contain ingredients suitable for protecting the fibrous structures of the present invention from degradation, such as via UV light.
  • the fibrous structure for example dry fibrous structure, of the present invention may be formed into a roll according to a method comprising the step of spirally winding the fibrous structure, for example dry fibrous structure, comprising a surface care composition (bacteriophage composition) comprising one or more bacteriophage to form a fibrous structure, for example dry fibrous structure, roll according to the present invention.
  • a surface care composition bacteriophage composition
  • the surface care composition of the present invention comprises one or more bacteriophage.
  • the bacteriophage composition comprises two or more and/or three or more and/or four or more and/or five or more and/or a cocktail of bacteriophage.
  • the bacteriophage composition of the present invention comprises six bacteriophage, such as the bacteriophage cocktail LISTSHIELDTM (LMP- 102TM), commercially available from Intralytix, Inc., Baltimore, Maryland.
  • the term "bacteriophage” refers to a particular bacteriophage that is effective against one or more bacterial strains. As used in this context, "effective against” means that the referenced bacteriophage infects, lyses, destructs, disrupts, kills, inhibits the growth of, reduces, inactivates or is otherwise effective against to the referenced strain of bacteria. In one example, the bacteriophage is a lytic bacteriophage, and therefore is capable of infecting and killing the target bacteria.
  • bacteria or “target bacteria” refer to an undesirable microorganism susceptible to infection, lysis, destruction (e.g., apoptosis), disruption, death, or inhibited growth, or any alternate mode of cell death caused by a bacteriophage. Different bacteriophage may infect different strains of bacteria with different results, or may infect some strains of bacteria but not others.
  • the bacteria or target bacteria is pathogenic bacteria (i.e., bacteria that are capable of causing infection).
  • other bacteria such as bacteria that are the source of malodor or other undesirable characteristics, are appropriate target bacterial as well.
  • the bacteriophage may be, independently, wild-type or genetically modified, or any combination thereof.
  • one or more of the bacteriophage present in the bacteriophage composition are wild-type.
  • all of the bacteriophage present in the bacteriophage composition are wild-type.
  • one or more of the bacteriophage is a lytic bacteriophage, and is therefore capable of infection, destruction, and bacterial cell death.
  • one or more of the bacteriophage is of the taxonomic family selected from the group consisting of Siphoviridae, Podoviridae, Myoviridae, and any combinations thereof. In one example, one or more of the bacteriophage is of the taxonomic family Myoviridae. In one example, all of the bacteriophage is of the taxonomic family Myoviridae.
  • one or more of the bacteriophage is a lytic bacteriophage of the taxonomic family Myoviridae.
  • the bacteriophage composition comprises two or more bacteriophage, then two or more of the bacteriophage are a lytic bacteriophage of the taxonomic family Myoviridae.
  • the bacteriophage composition comprises three or more bacteriophage, then three or more of the bacteriophage are a lytic bacteriophage of the taxonomic family Myoviridae.
  • the bacteriophage is a lytic bacteriophage of the taxonomic family Myoviridae and the taxonomic subfamily Teequatrovirinae.
  • the bacteriophage is a lytic T4 phage.
  • Non-limiting examples include Enter Obacteria phage T2, Enter obacteria phage T4, Enter obacteria phage T6, phage JS10, phage JS98, phage RB51, and any combinations thereof.
  • the bacteriophage is effective against gram-positive pathogenic bacteria. In one example herein, the bacteriophage is effective against gram-negative pathogenic bacteria. In one example, herein the bacteriophage is effective against a combination of gram-negative and gram-positive pathogenic bacteria.
  • the bacteriophage is effective against Enterobacterium such as, for example, Salmonella, Escherichia, or Shigella. Additionally or alternatively, one of more of the bacteriophage is effective against a strain of bacteria of a taxonomic genus selected from the group consisting of Streptococcus, Escherichia, Salmonella, Listeria, Shigella, Campylobacter, Clostridium, Staphylococcus, Pseudomonas, Mycobacterium, and any combinations thereof.
  • Enterobacterium such as, for example, Salmonella, Escherichia, or Shigella.
  • a strain of bacteria of a taxonomic genus selected from the group consisting of Streptococcus, Escherichia, Salmonella, Listeria, Shigella, Campylobacter, Clostridium, Staphylococcus, Pseudomonas, Mycobacterium, and any combinations thereof.
  • one of more of the bacteriophage is effective against a strain of bacteria of a taxonomic genus selected from the group consisting of Streptococcus, Escherichia, Salmonella, Listeria, Staphylococcus, Pseudomonas, and any combinations thereof.
  • the bacteriophage is effective against Streptococcus.
  • the Streptococcus bacteria is Streptococcus pyogenes.
  • the bacteriophage is effective against Escherichia.
  • the Escherichia bacteria is Escherichia coli.
  • the bacteriophage is effective against Salmonella.
  • the Salmonella bacteria is selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella heidelberg, Salmonella newport, Salmonella hadar, and any combinations thereof.
  • the Salmonella bacteria is Salmonella enteritidis.
  • the bacteriophage is a combination of bacteriophage such as, for example, SALMOLYSETM, containing six bacteriophage and commercially available from Intralytics, Inc., Baltimore, Maryland.
  • the bacteriophage is a combination of bacteriophage such as, for example, SALMOFRESHTM, containing six bacteriophage and commercially available from Intralytix, Inc., Baltimore, Maryland.
  • the bacteriophage may be, for example, SALMONELEXTM, a broad-spectrum combination of bacteriophage commercially available from Micreos B.V.
  • the bacteriophage is effective against Listeria.
  • the Listeria bacteria is Listeria monocytogenes.
  • the bacteriophage is a combination of bacteriophage such as, for example, LISTSHIELDTM (LMP-102TM), containing six bacteriophage and commercially available from Intralytix, Inc., Baltimore, Maryland.
  • the bacteriophage may be, for example, LISTEXTM PI 00, a broad-spectrum combination of bacteriophage commercially available from Micreos B.V.
  • the bacteriophage is effective against Shigella.
  • the Shigella bacteria is Shigella sonnei or Shigella flexneri.
  • the bacteriophage is effective against Campylobacter.
  • the Campylobacter bacterium is Campylobacter jejuni.
  • the bacteriophage is effective against Clostridium.
  • the Clostridium bacterium is Clostridium botulinum.
  • the bacteriophage is effective against Staphylococcus. In one example, the
  • Staphylococcus bacteria is Staphylococcus aureus.
  • the bacteriophage is effective against Pseudomonas.
  • the Pseudomonas bacteria is Pseudomonas aeruginosa.
  • the bacteriophage is effective against Mycobacterium.
  • the Mycobacterium bacteria is Mycobacterium tuberculosis.
  • At least one of the one or more bacteriophage is a lytic bacteriophage. In another example, at least one of the one or more bacteriophage is effective against a strain of bacteria of a taxonomic genus selected from the group consisting of Streptococcus, Escherichia, Salmonella, Listeria, Shigella, Campylobacter, Clostridium, Staphylococcus, Pseudomonas, Mycobacterium, and any combinations thereof. In still another example, at least one of the one or more bacteriophage is effective against a strain of Streptococcus bacteria.
  • At least one of the one or more bacteriophage is effective against a strain of Escherichia bacteria. In still another example, at least one of the one or more bacteriophage is effective against a strain of Salmonella bacteria. In yet another example, at least one of the one or more bacteriophage is effective against a strain of Listeria bacteria. In even another example, at least one of the one or more bacteriophage is effective against a strain of Shigella bacteria. In still yet another example, at least one of the one or more bacteriophage is effective against a strain of Campylobacter bacteria. In even still yet another example, at least one of the one or more bacteriophage is effective against a strain of Clostridium bacteria.
  • At least one of the one or more bacteriophage is effective against a strain of Staphylococcus bacteria. In one example, at least one of the one or more bacteriophage is effective against a strain of Pseudomonas bacteria. In one example, at least one of the one or more bacteriophage is effective against a strain of Mycobacterium bacteria. In another example, at least one of the one or more bacteriophage is of a taxonomic family selected from the group consisting of Siphoviridae, Podoviridae, Myoviridae, and combinations thereof. In still another example, at least one of the one or more of the bacteriophage is of the taxonomic family Myoviridae.
  • the dry fibrous structures of the present invention may be made by applying a surface care composition (bacteriophage composition) comprising one or more bacteriophage to a fibrous structure, such as by contacting a surface of the fibrous structure with the surface care composition such that a fibrous structure, for example a dry fibrous structure, comprising the bacteriophage composition is produced.
  • a surface care composition comprising one or more bacteriophage
  • Non-limiting examples of applying a surface care composition of the present invention to a fibrous structure to produce a dry fibrous structure according to the present invention include printing, such as gravure roll printing and/or flexographic printing, spraying, delivering via a permeable roll applicator, dipping, brushing, extruding, and other suitable means known in the art for delivering an additive to a fibrous structure.
  • the surface care composition of the present invention is a liquid composition at the time of application and/or if the fibrous structure contains a liquid such that the fibrous structure exhibits a water content of 20% or greater by weight of the fibrous structure then the fibrous structure may be dried by suitable drying means to produce the dry fibrous structure of the present invention.
  • the present invention is further directed to methods of contacting a surface with one or more bacteriophage, comprising the step of contacting the surface with a fibrous structure, for example a dry fibrous structure, comprising one or more bacteriophage according to the present invention.
  • a fibrous structure for example a dry fibrous structure, comprising one or more bacteriophage according to the present invention.
  • the surface may be any surface that is susceptible to bacterial contamination.
  • the surface is contacted with the fibrous structure, for example dry fibrous structure, such that at least a portion of the surface care composition (bacteriophage composition) is transferred from the fibrous structure to the surface.
  • the method for treating a surface may further comprise contacting the surface with a liquid concurrently with and/or prior to contacting the surface with the fibrous structure, for example dry fibrous structure.
  • the method for treating a surface may further comprise the step of contacting the fibrous structure, for example dry fibrous structure, of the present invention with a liquid to produce a liquid-containing fibrous structure; and then contacting the surface to be treated with the liquid-containing fibrous structure, for example such that at least a portion of the surface care composition (bacteriophage composition) is transferred to the surface.
  • the fibrous structure for example dry fibrous structure
  • the method for treating a surface may further comprise the step of contacting the fibrous structure, for example dry fibrous structure, of the present invention with a liquid to produce a liquid-containing fibrous structure; and then contacting the surface to be treated with the liquid-containing fibrous structure, for example such that at least a portion of the surface care composition (bacteriophage composition) is transferred to the surface.
  • the method for treating a surface may further comprise contacting the surface with a liquid composition concurrently with and/or prior to contact the surface with the liquid-containing fibrous structure.
  • the surface may be a surface found within a kitchen ("a kitchen surface").
  • kitchen surfaces include surfaces susceptible to bacterial contamination through ordinary use, commonly touched by a user, in contact with food, or otherwise in contact with a source of bacteria (whether interior or exterior to the kitchen item) such as sinks; drains; faucets; faucet handles; refrigerators, freezers, microwaves, ovens, stoves, toasters, and other kitchen appliances; cabinets; shelves; countertops; drawers; backsplashes; walls; floors; fans; and the like, including any single item of the foregoing or any combination thereof.
  • the surface may be a surface found within a bathroom ("a bathroom surface)"
  • bathroom surfaces include surfaces susceptible to bacterial contamination through ordinary use, commonly touched by a user, or otherwise in contact with a source of bacteria, (whether interior or exterior to the bathroom item) such as sinks; drains, faucets; faucet handles; cabinets; shelves; countertops; drawers; backsplashes; walls; floors; fans; showers, bathtubs or other basins; toilets; soap dispensers; towel dispensers; and the like, including single item of the foregoing or any combination thereof.
  • the surface may be skin, or another epithelial surface, of a human or other animal (including, for example, a companion animal such as a dog or cat) ("an epithelial surface").
  • the one or more bacteriophage is releasably transferred from the dry fibrous structure to the surface.
  • from about 10 PFUs to about 10 10 PFUs of the one or more bacteriophage is releasably transferred from the dry fibrous structure to the surface.
  • such transfer is readily accomplished wherein the bacteriophage composition is contained on a surface of the dry fibrous structure that may come in contact with the surface that is susceptible to bacterial contamination.
  • the two-ply tissue product may comprise bacteriophage composition on the outer surface of one of the plies of the product.
  • the facial tissue may comprise bacteriophage composition on the surface of the tissue that comes into contact with skin during ordinary use.
  • the surface susceptible to bacterial contamination is substantially dry.
  • a kitchen countertop that is substantially dry may be treated with a fibrous structure herein, such as a paper towel.
  • the methods of the invention comprise wetting the fibrous structure prior to contacting the surface with at least a portion of the fibrous structure.
  • the surface susceptible to bacterial contamination is not substantially dry.
  • a user could wet the surface, such as to spray a kitchen countertop with water or a standard liquid cleaner prior to wiping the countertop with an fibrous structure herein, such as a paper towel.
  • the wetting occurs prior to contacting the surface with at least a portion of the fibrous structure.
  • the methods could also include wetting the fibrous structure prior to contacting the surface with at least a portion of the fibrous structure.
  • the bacteriophage composition and/or bacteriophages provide residual performance to help prevent and/or inhibit and/or minimize bacteria colonization on the surface previously treated with a dry fibrous structure according to the present invention.
  • Example 1 This example describes the feasibility of transferring bacteriophage from a disposable paper towel onto a solid surface.
  • bacteriophage can be successfully transferred from a paper towel onto a solid surface.
  • about 5 of the possible 8 logs of bacteriophage present on the paper towel are transferred from the paper towel onto the slide. This testing is completed with paper towel that had not completely dried and carriers that are also partially wet. While paper towels are typically used on moist surfaces, the paper towel itself is initially dry.
  • Example 2 - describes the impact on the amount of bacteriophage transferred to the surface based on whether the paper towel is pre- wetted or dry during use and whether the solid surface that is wiped is pre- wetted or dry during wiping.
  • the highest amount of bacteriophage transferred from a paper towel to a surface occurs when both the paper towel and the surface are pre- wetted (water content of 20% or greater by weight of the dry fibrous structure at time of use). The least amount of transfer is seen when both the paper towel and the surface are dry (water content less than 20% by weight of the dry fibrous structure at time of use).
  • using a dry towel on a wet or dry surface has a similar level of bacteriophage transfer.
  • a similar level of bacteriophage transfer is also seen when a pre-wetted paper towel is used on a wet or dry surface.
  • Examples of dry fibrous structures are produced utilizing a cellulosic pulp fiber furnish consisting of about 55% refined softwood furnish consisting of about 44% Northern Bleached Softwood Kraft (Bowater), 44% Northern Bleached Softwood Kraft (Celgar) and 12% Southern Bleached Softwood Kraft (Alabama River Softwood, Weyerhaeuser); about 30% of unrefined hardwood Eucalyptus Bleached Kraft consisting of about 80% (Fibria) and 20% NBHK (Aspen) (Peace River); and about 15% of an unrefined furnish consisting of a blend of about 27%Northern Bleached Softwood Kraft (Bowater), 27% Northern Bleached Softwood Kraft (Celgar), 42% Eucalyptus Bleached Kraft (Fibria) and 7% Southern Bleached Kraft (Alabama River Softwood, Weyerhaeuser).
  • the 55% refined softwood is refined as needed to maintain target wet burst at the reel. Any furnish preparation and
  • a 3% active solution Kymene 5221 is added to the refined softwood line prior to an in-line static mixer and 1% active solution of Wickit 1285, an ethoxylated fatty alcohol available from Ashland Inc. is added to the unrefined Eucalyptus Bleached Kraft (Fibria) hardwood furnish. The addition levels are 21 and 1 lbs active/ton of paper, respectively.
  • the refined softwood and unrefined hardwood and unrefined NBSK/SSK/Eucalyptus bleached kraft/NDHK thick stocks are then blended into a single thick stock line followed by addition of 1% active carboxymethylcellulose (CMC- Finnfix) solution at 7 lbs active/ton of paper towel, and optionally, a softening agent may be added.
  • CMC- Finnfix active carboxymethylcellulose
  • the thick stock is then diluted with white water at the inlet of a fan pump to a consistency of about 0.15% based on total weight of softwood, hardwood and simulated broke fiber.
  • the diluted fiber slurry is directed to a non layered configuration headbox such that the wet web formed onto a Fourdrinier wire (foraminous wire).
  • a fines retention/drainage aid may be added to the outlet of the fan pump.
  • the Fourdrinier wire is of a 5-shed, satin weave configuration having 87 machine-direction and 76 cross-direction monofilaments per inch, respectively.
  • the speed of the Fourdrinier wire is about 750 fpm (feet per minute).
  • the embryonic wet web is transferred from the Fourdrinier wire at a fiber consistency of about 24% at the point of transfer, to a belt, such as a patterned belt through-air-drying resin carrying fabric.
  • a belt such as a patterned belt through-air-drying resin carrying fabric.
  • the speed of the patterned through-air-drying fabric is approximately the same as the speed of the Fourdrinier wire.
  • the embryonic wet web may be transferred to a patterned belt and/or fabric that is traveling slower, for example about 20% slower than the speed of the Fourdrinier wire (for example a wet molding process).
  • the web While remaining in contact with the patterned belt, the web is pre-dried by air blow-through pre-dryers to a fiber consistency of about 65% by weight.
  • the semi-dry web is transferred to a Yankee dryer and adhered to the surface of the Yankee dryer with a sprayed creping adhesive.
  • the creping adhesive is an aqueous dispersion with the actives consisting of about 75% polyvinyl alcohol, and about 25% CREPETROL ® R6390.
  • a crepe aid consisting of CREPETROL ® A3025 may be applied.
  • CREPETROL ® R6390 and CREPETROL ® A3025 are commercially available from Ashland Inc. (formerly Hercules Inc.).
  • the creping adhesive diluted to about 0.15% adhesive solids and delivered to the Yankee surface at a rate of about 2# adhesive solids based on the dry weight of the web.
  • the fiber consistency is increased to about 97% before the web is dry creped from the Yankee with a doctor blade.
  • the doctor blade has a bevel angle of about 45° and is positioned with respect to the Yankee dryer to provide an impact angle of about 101° and the reel is run at a speed that is about 15% faster than the speed of the Yankee.
  • the doctor blade may have a bevel angle of about 25° and be positioned with respect to the Yankee dryer to provide an impact angle of about 81° and the reel is run at a speed that is about 10% slower than the speed of the Yankee.
  • the Yankee dryer is operated at a temperature of about 177 °C and a speed of about 800 fpm.
  • the fibrous structure is wound in a roll using a surface driven reel drum having a surface speed of about 656 feet per minute.
  • the fibrous structure may be subsequently converted into a two-ply paper towel product having a basis weight of about 45 to 54 g/m .
  • a bacteriophage composition may be applied to the fibrous structure to produce a dry fibrous structure (dry paper towel) comprising the bacteriophage composition by any suitable means, for example by printing on the bacteriophage composition to one or more surfaces of the fibrous structure.
  • the water (moisture) content present in a fibrous structure is measured using the following Water Content Test Method.
  • a fibrous structure or portion thereof (“sample") is placed in a conditioned room at a temperature of 73°F ⁇ 4°F (about 23°C ⁇ 2.2°C) and a relative humidity of 50% ⁇ 10% for at least 24 hours prior to testing.
  • the weight of the sample is recorded when no further weight change is detected for at least a 5 minute period. Record this weight as the "equilibrium weight" of the sample.
  • the water (moisture) content of the sample is calculated as follows:
  • Basis weight of a fibrous structure sample is measured by selecting twelve (12) individual fibrous structure samples and making two stacks of six individual samples each. If the individual samples are connected to one another vie perforation lines, the perforation lines must be aligned on the same side when stacking the individual samples.
  • a precision cutter is used to cut each stack into exactly 3.5 in. x 3.5 in. squares. The two stacks of cut squares are combined to make a basis weight pad of twelve squares thick. The basis weight pad is then weighed on a top loading balance with a minimum resolution of 0.01 g.
  • the top loading balance must be protected from air drafts and other disturbances using a draft shield. Weights are recorded when the readings on the top loading balance become constant.
  • the Basis Weight is calculated as follows:
  • Basis Weight Weight of basis weight pad (g) x 3000 ft
  • Basis Weight Weight of basis weight pad (g) x 10,000 cm 2 /m 2
  • Bone Dry Basis Weight Basis Weight (g/ m ) x ( (100% - % Water per Water Content Test (g/cm 2 ) Method) / 100) / 10,000
  • Thickness of a fibrous structure and/or sanitary tissue product is measured using a ProGage Thickness Tester (Th wing- Albert Instrument Company, West Berlin, NJ) with a pressure foot diameter of 2.00 inches (area of 3.14 in 2 ) at a pressure of 95 g/in 2.
  • a ProGage Thickness Tester Thi wing- Albert Instrument Company, West Berlin, NJ
  • Four (4) samples are prepared by cutting of a usable unit such that each cut sample is at least 2.5 inches per side, avoiding creases, folds, and obvious defects.
  • An individual specimen is placed on the anvil with the specimen centered underneath the pressure foot. The foot is lowered at 0.03 in/sec to an applied pressure of 95 g/in . The reading is taken after 3 sec dwell time, and the foot is raised. The measure is repeated in like fashion for the remaining 3 specimens.
  • the caliper is calculated as the average caliper of the four specimens and is reported in mils (0.001 in) to the nearest 0.1 mils. Conversion to
  • the density of a web sample is measured by dividing the Basis Weight of the web sample by the Thickness of the web sample. Density units are reported as g/cm .
  • Peak Elongation, Tensile Strength, TEA and Tangent Modulus are measured on a constant rate of extension tensile tester with computer interface (a suitable instrument is the EJA Vantage from the Thwing-Albert Instrument Co. Wet Berlin, NJ) using a load cell for which the forces measured are within 10% to 90% of the limit of the cell.
  • Both the movable (upper) and stationary (lower) pneumatic jaws are fitted with smooth stainless steel faced grips, 25.4 mm in height and wider than the width of the test specimen. An air pressure of about 60 psi is supplied to the jaws.
  • Eight usable units of a fibrous structure sample are divided into two stacks of four samples each.
  • the samples in each stack are consistently oriented with respect to machine direction (MD) and cross direction (CD).
  • One of the stacks is designated for testing in the MD and the other for CD.
  • Using a one inch precision cutter (Thwing Albert JDC-1-10, or similar) cut 4 MD strips from one stack, and 4 CD strips from the other, with dimensions of 1.00 in + 0.01 in wide by 3.0 - 4.0 in long.
  • Each strip of one usable unit thick will be treated as a unitary specimen for testing.
  • the break sensitivity is set to 80%, i.e., the test is terminated when the measured force drops to 20% of the maximum peak force, after which the crosshead is returned to its original position.
  • Tensile Strength is the maximum peak force (g) divided by the sample width (in) and reported as g/in to the nearest 1 g/in.
  • Adjusted Gauge Length is calculated as the extension measured at 3.0 g of force (in) added to the original gauge length (in).
  • Peak Elongation is calculated as the extension at maximum peak force (in) divided by the Adjusted Gauge Length (in) multiplied by 100 and reported as % to the nearest 0.1%
  • Total Energy is calculated as the area under the force curve integrated from zero extension to the extension at the maximum peak force (g*in), divided by the product of the adjusted Gauge Length (in) and specimen width (in) and is reported out to the nearest 1 g*in/in .
  • Tangent Modulus is the Modulus at 15 g/cm.
  • the Tensile Strength (g/in), Peak Elongation (%), Total Energy (g*in/in ) and Modulus (g/cm), which is the Tangent Modulus at 15 g/cm), are calculated for the four CD unitary specimens and the four MD unitary specimens. Calculate an average for each parameter separately for the CD and MD specimens.
  • Geometric Mean Tensile Strength Square Root of [MD Tensile Strength (g/in) x CD Tensile Strength (g/in)]
  • Geometric Mean Peak Elongation Square Root of [MD Elongation (%) x CD Elongation
  • Geometric Mean TEA Square Root of [MD TEA (g*in/in 2 ) x CD TEA (g*in/in 2 )]
  • Total TEA MD TEA (g*in/in 2 ) + CD TEA (g*in/in 2 )
  • Total Modulus MD Modulus (g/cm) + CD Modulus (g/cm)
  • the initial total wet tensile of a dry fibrous structure is determined using a Thwing- Albert EJA Material Tester Instrument, Cat. No. 1350, equipped with 5000 g load cell available from Thwing-Albert Instrument Company, 14 Collings Ave. W. Berlin, N.J. 08091. 10% of the 5000 g load cell is utilized for the initial total wet tensile test.
  • a water/0.1% Pegosperse® ML200 available from Lonza Inc. of Allendale, N.J.
  • ML200 available from Lonza Inc. of Allendale, N.J.
  • the solution is continuously added until the sample strip is visually determined to be completely saturated between the upper and lower jaws.
  • the load cell is re-adjusted to read 0 + 0.5 grams f o rC e-
  • the sample strip is then strained at a rate of 10.16 cm/minute (4 inches/minute) and continues until the sample strip is strained past its failure point (failure point being defined as the point on the force- strain curve where the sample strip falls to 50% of its peak strength after it has been strained past its peak strength).
  • the straining of the sample strip is initiated between 5-10 seconds after the sample is initially wetted.
  • the initial result of the test is an array of data points in the form of load (gramS force ) versus strain (where strain is calculated as the crosshead displacement (cm of jaw movement from starting point) divided by the initial separation distance (cm) between the upper and lower jaws after the pre-test.
  • MD machine direction
  • CD cross-machine direction, i.e., 90° from MD
  • ITWT(g/inch) Peak Load MD (g f )/l (inch width )+Peak Load CD (g f )/l (inch width )
  • Percent Roll Compressibility is determined using the Roll Diameter Tester 1000 as shown in Figure 1. It is comprised of a support stand made of two aluminum plates, a base plate 1001 and a vertical plate 1002 mounted perpendicular to the base, a sample shaft 1003 to mount the test roll, and a bar 1004 used to suspend a precision diameter tape 1005 that wraps around the circumference of the test roll. Two different weights 1006 and 1007 are suspended from the diameter tape to apply a confining force during the uncompressed and compressed measurement. All testing is performed in a conditioned room maintained at about 23 °C + 2 C° and about 50% + 2% relative humidity.
  • the diameter of the test roll is measured directly using a Pi® tape or equivalent precision diameter tape (e.g. an Executive Diameter tape available from Apex Tool Group, LLC, Apex, NC, Model No. W606PD) which converts the circumferential distance into a diameter measurement so the roll diameter is directly read from the scale.
  • the diameter tape is graduated to 0.01 inch increments with accuracy certified to 0.001 inch and traceable to NIST.
  • the tape is 0.25 in wide and is made of flexible metal that conforms to the curvature of the test roll but is not elongated under the 1100 g loading used for this test. If necessary the diameter tape is shortened from its original length to a length that allows both of the attached weights to hang freely during the test, yet is still long enough to wrap completely around the test roll being measured.
  • the cut end of the tape is modified to allow for hanging of a weight (e.g. a loop). All weights used are calibrated, Class F hooked weights, traceable to NIST.
  • the aluminum support stand is approximately 600 mm tall and stable enough to support the test roll horizontally throughout the test.
  • the sample shaft 1003 is a smooth aluminum cylinder that is mounted perpendicularly to the vertical plate 1002 approximately 485 mm from the base. The shaft has a diameter that is at least 90% of the inner diameter of the roll and longer than the width of the roll.
  • a small steal bar 1004 approximately 6.3 mm diameter is mounted perpendicular to the vertical plate 1002 approximately 570 mm from the base and vertically aligned with the sample shaft.
  • the diameter tape is suspended from a point along the length of the bar corresponding to the midpoint of a mounted test roll.
  • the height of the tape is adjusted such that the zero mark is vertically aligned with the horizontal midline of the sample shaft when a test roll is not present.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Textile Engineering (AREA)
  • Cleaning Implements For Floors, Carpets, Furniture, Walls, And The Like (AREA)

Abstract

L'invention concerne des structures fibreuses contenant une composition d'entretien de surface, et plus particulièrement des structures fibreuses sèches contenant une composition d'entretien de surface comprenant un ou plusieurs bactériophages, des procédés de fabrication de celui-ci, et des procédés pour le traitement de surfaces au moyen de ces structures.
EP15702120.5A 2014-01-24 2015-01-22 Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage Withdrawn EP3096620A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931129P 2014-01-24 2014-01-24
PCT/US2015/012420 WO2015112690A1 (fr) 2014-01-24 2015-01-22 Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage

Publications (1)

Publication Number Publication Date
EP3096620A1 true EP3096620A1 (fr) 2016-11-30

Family

ID=52440934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15702120.5A Withdrawn EP3096620A1 (fr) 2014-01-24 2015-01-22 Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage

Country Status (2)

Country Link
EP (1) EP3096620A1 (fr)
WO (1) WO2015112690A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994771A (en) 1975-05-30 1976-11-30 The Procter & Gamble Company Process for forming a layered paper web having improved bulk, tactile impression and absorbency and paper thereof
US4300981A (en) 1979-11-13 1981-11-17 The Procter & Gamble Company Layered paper having a soft and smooth velutinous surface, and method of making such paper
US5643588A (en) 1994-11-28 1997-07-01 The Procter & Gamble Company Diaper having a lotioned topsheet
US5635191A (en) 1994-11-28 1997-06-03 The Procter & Gamble Company Diaper having a lotioned topsheet containing a polysiloxane emollient
US5609587A (en) 1995-08-03 1997-03-11 The Procter & Gamble Company Diaper having a lotioned topsheet comprising a liquid polyol polyester emollient and an immobilizing agent
US5607760A (en) 1995-08-03 1997-03-04 The Procter & Gamble Company Disposable absorbent article having a lotioned topsheet containing an emollient and a polyol polyester immobilizing agent
KR20030009338A (ko) * 2000-01-11 2003-01-29 인트랄리틱스, 인크. 생복합체를 제조하기 위해 생분해성 매트릭스로 사용되는중합체 블렌드
US7166292B2 (en) 2001-06-29 2007-01-23 The Procter & Gamble Company Top-biased beneficial components on substrates
EP1458856B1 (fr) 2001-12-13 2012-06-13 Societe Des Produits Nestle S.A. Phages isolees et leur utilisation dans des produits alimentaires ou la nourriture pour animaux familiers
CA2537725A1 (fr) 2003-09-03 2005-03-31 Intralytix, Inc. Procede de vaccination de la volaille par un lysat bacteriophage
AU2004282563A1 (en) * 2003-10-15 2005-04-28 Board Of Regents, The University Of Texas System Viral fibers
DE102007054127A1 (de) * 2007-11-11 2009-05-14 Birgit Riesinger Hygiene- oder Pflegeartikel, aufweisend einen Anteil an hydroaktiven Polymeren, und eine Zubereitung aufweisend Bakteriophagen oder mindestens einen Bestandteil derselben
US8017534B2 (en) 2008-03-17 2011-09-13 Kimberly-Clark Worldwide, Inc. Fibrous nonwoven structure having improved physical characteristics and method of preparing
KR101151532B1 (ko) 2008-12-24 2012-05-30 씨제이제일제당 (주) 신규한 박테리오파지 및 이를 포함하는 항균 조성물
GB201110647D0 (en) * 2011-06-23 2011-08-10 Fixed Phage Ltd Delivery of viral agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2015112690A1 *

Also Published As

Publication number Publication date
WO2015112690A1 (fr) 2015-07-30

Similar Documents

Publication Publication Date Title
US11918001B2 (en) Fibrous structures comprising a surface care composition and methods for making and using same
AU2011346720B2 (en) Dispersible wet wipes constructed with a plurality of layers having different densities and methods of manufacturing
US6475501B1 (en) Antiviral compositions for tissue paper
CN104995353B (zh) 微原纤化材料成分的湿铺片材
US10765613B2 (en) Stable lotion emulsion composition and wet wipe
AU2008334327B2 (en) Self-indicating wipe for removing bacteria from a surface
AU2010233365B2 (en) Wet wipes having a liquid wipe composition with anti-adhesion component
MX2012013258A (es) Paños humedos dispersables fabricados usando fibras de celulas cortas para dispersibilidad mejorada.
EP1221851B1 (fr) Compositions antivirales pour papier de soie
MX2012013259A (es) Paños humedos dispersables de una sola hoja con dispersibilidad mejorada.
AU2011262334A1 (en) Dispersible wet wipes made using short cellulose fibers for enhanced dispersibility
US11039988B2 (en) Wet wipe comprising a lotion
KR100516076B1 (ko) 피부에 자극적이지 않은 항바이러스 제제를 함유하는 티슈제품
JP5314219B1 (ja) 水溶液
EP3096620A1 (fr) Structures fibreuses comprenant une composition d'entretien de surface et un bactériophage
JP2000110099A (ja) 食品用抗菌紙
JPH0449932A (ja) 積層シート状清掃物品
TW202104724A (zh) 抗菌紙及其製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180710